Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection.

Kanaan, Nada;Kabamba-Mukadi, Benoît;Maréchal, Céline;Pirson, Yves;Hassoun, Ziad;et.al.
(2012) Journal of Clinical Virology — Vol. 55, n° 3, p. 233-238 (2012)

Files

KanaanJClinVirol201255233-238.pdf
  • Restricted Access
  • Adobe PDF
  • 273 KB

Details

Authors
  • Kanaan, NadaUCLouvain
    Author
  • Maréchal, CélineUCLouvain
    Author
  • Pirson, YvesUCLouvain
    Author
  • Beguin, ClaireUCLouvain
    Author
  • Goffin, EricUCLouvain
    Author
  • Hassoun, ZiadUCLouvain
    Author
Show more
Abstract
BACKGROUND: Limited data is available on the risk of hepatitis B virus (HBV) reactivation in patients with resolved infection undergoing kidney transplantation. It is generally thought that this risk is negligible. OBJECTIVES: To evaluate the incidence of HBV reactivation in such patients, and the potential risk factors for reactivation. STUDY DESIGN: Retrospective cohort study including 93 patients transplanted with a kidney between 1995 and 2007 who had evidence of resolved HBV infection (HBsAg negative, anti-HBc positive, anti-HBs positive or negative, and normal liver enzymes). HBV reactivation was defined as HBsAg reversion with HBV DNA>2000 IU/mL. RESULTS: Six patients experienced HBsAg reversion followed by HBV reactivation, 3 within the first post-transplant year. Immunosuppression regimen was similar in patients with and without reactivation. Among patients with reactivation only one was positive for anti-HBs antibodies at time of transplantation; these were progressively lost before reactivation. The odds ratio for reactivation in patients without anti-HBs antibodies at transplantation compared to those with anti-HBs antibodies was 26 (95% CI [2.8-240.5], p=0.0012). In patients with anti-HBs antibody titer above 100 IU/L, no reactivation was observed. CONCLUSIONS: Reactivation rate of resolved hepatitis B is not negligible in patients without anti-HBs antibodies at transplantation. We suggest monitoring of liver tests and HBV serology including HBsAg and anti-HBs antibodies after transplantation as well as vaccination pre- and post-transplantation in all patients, including those with resolved hepatitis B, aiming at maintaining anti-HBs antibody level above 100 IU/L.
Affiliations

Citations

Kanaan, N., Kabamba-Mukadi, B., Maréchal, C., Pirson, Y., Beguin, C., Goffin, E., & Hassoun, Z. (2012). Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. Journal of Clinical Virology, 55(3), 233-238. https://doi.org/10.1016/j.jcv.2012.07.015 (Original work published 2012)